Paper Details

  1. Home
  2. Paper Details

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Author: EasonJames, FunderburgNicholas, GoodrichJames, HeeraJayvant, KalinowskaMagdalena, LedermanMichael M, MayerHoward, RajicicNatasa, ValdezHernan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined whether maraviroc treatment for HIV-1 infection leads to larger CD4(+) T cell rises than its antiviral activity alone. Maraviroc treatment resulted in more rapid decreases in certain markers of immune activation and inflammation than efavirenz. These decreases were correlated with increased CD4(+) T cell gains.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation. METHODS AND FINDINGS: Thirty maraviroc-treated patients f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950842/

データ提供：米国国立医学図書館（NLM）

Maraviroc: A Promising Drug for HIV Treatment

The field of HIV research is constantly evolving, with new treatments and therapies being developed to improve the lives of those affected by this disease. This study delves into the exciting potential of maraviroc, a drug that has shown promise in boosting CD4+ T cell counts in patients with HIV-1. Researchers are particularly interested in how maraviroc might work by modulating T cell activation and inflammation, which could ultimately lead to improved immune response and overall health for patients.

Maraviroc's Effect on Immune Markers

The study, conducted by comparing maraviroc-treated patients to those receiving efavirenz, revealed that maraviroc tended to lead to quicker reductions in CD38 expression on CD4+ T cells and plasma D-dimer concentrations. This is an important finding, as these markers are associated with immune activation and inflammation. Furthermore, maraviroc maintained stable levels of high-sensitivity C-reactive protein, while efavirenz saw an increase. These observations suggest that maraviroc might have a beneficial effect on immune function, potentially leading to better outcomes for patients.

Implications for HIV Treatment

This study provides further evidence for the potential of maraviroc as an effective treatment for HIV-1. The findings suggest that maraviroc's effects on immune activation and inflammation could contribute to its positive impact on CD4+ T cell recovery. As a researcher who has seen the devastating effects of HIV, I am encouraged by these promising results. Further research is needed to fully understand the mechanisms behind maraviroc's beneficial effects, but this study provides a valuable step towards improving HIV treatment.

Dr.Camel's Conclusion

It's exciting to see how maraviroc might be working its magic on the immune system. Imagine a desert oasis providing much-needed relief from the harsh conditions – that's what maraviroc could be doing for people with HIV. It's not just about fighting the virus; it's about restoring the body's natural defenses and helping people live healthier lives.

Date :
  1. Date Completed 2011-03-07
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20949133

DOI: Digital Object Identifier

PMC2950842

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.